uniQure N.V. (QURE): Cash & Equivalents
$80.24M
As of 2025-12-31
$139.99M
As of 2026-03-31
-29.4%
3-year compound annual growth
-20.0%
5-year compound annual growth
-9.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $80.24M | -49.5% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $158.93M | -34.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $241.36M | +5.9% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $228.01M | -59.0% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $556.26M | +127.1% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $244.93M | -35.2% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $377.79M | +60.8% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $234.90M | +47.4% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $159.37M | +20.3% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $132.50M | -40.2% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $221.63M | +242.6% | 2018-03-14, Balance as of period end |
| 2014-12-31 | $64.69M | n/a | 2017-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.01M | -50.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $15.42M | -20.8% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $7.49M | +192.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗